MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


AIM WINNERS & LOSERS: EKF sees revenue up, Zotefoams gets broker lift

ALN

The following stocks are the leading risers and fallers on AIM on Tuesday.

----------

AIM - WINNERS

----------

Roebuck Food Group PLC, up 10% at 22.00 pence, 12-month range 13.59p-21.00p. The Dublin-based firm with divisions provided food sourcing and distribution services, ingredients and agricultural solutions says its GlasPort Bio unit has made ‘significant progress’ since it was acquired in February of last year. However, in Moorhead & McGavin/Foro Food Solutions, the plant-based ingredients division that supplies food services and manufacturing, had a ‘difficult’ 2025. ‘The UK Food Service market was particularly difficult,’ Roebuck adds. It notes, actions taken to keep a lid on costs does set the division up for ‘sales growth and profit recovery in 2026,’ however.

----------

Zotefoams PLC, up 5.4% at 412.00 pence, 12-month range 222.00p-479.88p. Shares in the Croydon, London-headquartered foams, insulation, seals and interior trims provider rise as broker Berenberg raises its price target for the company’s stock to 590 pence from 540p and reiterates its ’buy’ rating.

----------

AIM - LOSERS

----------

EKF Diagnostics Holdings PLC, down 7.2% at 25.24p, 12-month range 18.40p-32.00p. Expects to report 2025 revenue growth of 3% to £51.6 million from £50.2 million. The Cardiff-headquartered medical diagnostics company says gross margin stood at 51% for the period, improving from 48%. Adjusted earnings before interest, tax, depreciation, and amortisation are expected to increase around 10% to £12.4 million from £11.3 million, in line with consensus.

----------

Copyright 2026 Alliance News Ltd. All Rights Reserved.